Center Report to the SNMMI Board of Directors  
January 27, 2018  
Therapy Center of Excellence

**Center Mission:** Therapy CoE is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. Specifically, the center will bring together a centralized group of all constituents within this area creating a multidisciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:
(a) Provides a forum for members with similar interests  
(b) Provides expertise in TRT  
(c) Fosters research and education in TRT  
(d) Provides outreach to other professionals and organizations  
(e) Nurtures new membership in SNMMI

**Center Mission and SNMMI’s Strategic Plan:** The work of the Therapy Center applies to the following goals and objectives in SNMMI’s Strategic Plan:

**Goal A:** SNMMI members are known for high-quality, value-driven performance and delivery of patient-centered nuclear medicine practice.
   Objective 4. Expand continuing education options for practitioners.

**Goal B:** SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.
   Objective 1: Encourage and promote research in the field  
   Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.

**Goal E:** Patients and the medical community recognize the value of nuclear medicine, molecular imaging and radionuclide therapy.
   Objective 3. Improve collaboration with other medical societies.
Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

Objective 1: Strengthen membership numbers.
   d. Ensure enthusiasm.
      iii. Create a sense of community and networking opportunities among our members.

Therapy CoE President: Dan Pryma, MD

SNMMI Board members appointed to Therapy CoE Board: Bennett S. Greenspan, MD, FACNM, FACR; Jon Baldwin, DO; Suzanne Lapi, PhD

Date of Last meeting: Monday, June 12, 2017

Date of Next meeting: Friday, January 26, 2018 @ MWM

Update on Programs of the Center:

2018 SNMMI Mid-Winter Meeting CE sessions – MWM focused on Therapy:
   • Radionuclide Therapy and Dosimetry I: Dosimetry Methods and Clinical Experience
   • Radionuclide Therapy and Dosimetry II - Roles of the Physician and Technologist
   • Safety and Dosimetry in Pediatric Radioiodine Therapy
   • Radioiodine Therapy: Lessons from a Theranostics Trailblazer I and II
   • Theranostics - Neuroendocrine I and II
   • Theranostics – New Radiopharmaceuticals I and II
   • Theranostics in Practice I and II

2018 SNMMI Annual Meeting Categorical Sessions:
   • Radioiodine Theragnostics: Continuing the Update of the Controversies of the Management of Differentiated Thyroid Cancer
   • PSMA Radioligand Therapy (PRLT) of End-stage Prostate Cancer Patients Selected by PSMA PET/CT - The Power of Precision Oncology

2018 SNMMI Annual Meeting CE Session:
   • Prostate Cancer Theranostics and Bone Targeting Radiopharmaceutical Therapy
   • NET theranostics
   • Liver directed therapy
   • Emerging Theranostic targets
   • Thyroid theranostics
   • Nuts and Bolts
• 2018 Saul Hertz Award Winner is Richard Wahl, MD, FACNM, and he will speak in one of these sessions

Outreach Meetings:
• Multilateral Conference of Differentiated Thyroid Cancer
• Roundtable discussion on Targeted Radiotherapy with NCI

Outreach by Committee on Radiiodine Theragnostics (CORT):
• Coordination of one presentation and one panel sponsored by SNMMI at the July 2017 Thyroid Cancer World Congress in Boston.
• Coordination of a conjoint sponsored SNMMI and ATA presentations by two speakers for the ATA meeting in Victoria, Canada in October 2017.
• Coordination of a multi-lateral thyroid cancer meeting with the American Thyroid Association, European Thyroid Association, European Association of Nuclear Medicine, and the SNMMI.

Action Items in Progress/Pending:
• Launching additional committees of the Center
• Establishing the Therapy Center newsletter
• Follow-up with NCI on the TRT meeting
• ThyCa Initiative: bringing together local nuclear medicine physicians and ThyCa chapter facilitators to coordinate pro bono presentations by nuclear medicine physician in the region of the various ThyCa chapters on radiiodine imaging and therapy. Develop educational modules for these speakers.

Action Items Completed:  See programs above

Recommendations/Questions for the Board of Directors: N/A

Other Comments: N/A